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Abstract HAP1 (huntingtin associated protein) has previously
been found to interact with huntingtin (htt) in a glutamine length
dependent manner and has been proposed to play a role in the cell
specific neurodegeneration observed in Huntington’s disease
(HD). We have isolated mouse HAP1 (hap1) and have shown
that expression is not enriched in areas specifically affected in
HD. We have used the yeast two hybrid system to demonstrate
that htt amino acids 171^230 are necessary for the hap1-htt
binding and that hap1 does not interact with the transgene exon 1
protein in a transgenic model of HD.
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1. Introduction
Huntington’s disease (HD) is one of several neurodegener-
ative disorders caused by a CAG/polyglutamine expansion. In
addition to HD this includes spinal and bulbar muscular atro-
phy, dentatorubral pallidoluysian atrophy (DRPLA) and the
spinocerebellar ataxias: SCA1, SCA2, SCA3 (also known as
Machado Joseph disease), SCA6 (reviewed in [1]) and SCA7
[2]. The proteins harbouring the polyglutamine repeats all
have wide and overlapping expression patterns. It is likely
that the mutation acts by imparting a gain of function to
the respective protein and that the mechanism of neuronal
dysfunction and cell death is common to these diseases. De-
spite the overlapping expression pro¢les, the pattern of neuro-
pathology di¡ers strikingly between these diseases and the
factors governing this selective vulnerability are unknown [3].
The proteins that contain the polyglutamine expansions are
mostly novel and unrelated except for the presence of the
polyglutamine tract. One approach to gaining insights into
the normal function of these proteins, the molecular basis of
the pathogenesis and the selective vulnerability of certain neu-
rons is to identify interacting proteins. Huntingtin interactors
that have been identi¢ed using the yeast two hybrid system
include: htt associated protein (HAP1) [4], htt interacting pro-
tein (HIP1) [5,6] and a ubiquitin conjugating enzyme (hE2-
25K) [7]. HAP1 was isolated from a rat brain cDNA library
using the N-terminal 230 amino acids of htt containing 44
glutamine repeats [4]. Rat HAP1 has two isoforms, HAP1A
and HAP1B, and expression was reported to be exclusively in
brain [4]. HAP1 was found to bind to htt in a glutamine
length dependent manner, but its failure to bind to atrophin
with 21 repeats suggested that it did not bind non-selectively
to the polyglutamine tract [4]. The restriction of the expres-
sion pattern to brain and the modulation of the htt-HAP1
interaction by the length of the polyglutamine repeat sug-
gested that HAP1 might be involved in the molecular events
that lead to the onset of HD.
We have recently generated lines of mice transgenic for
exon 1 of the HD gene carrying highly expanded CAG repeats
that express an N-terminal htt protein [8]. Three transgenic
lines have been established: R6/1, (CAG)115 ; R6/2, (CAG)145 ;
and R6/5, (CAG)128ÿ156 that develop a progressive neurolog-
ical phenotype with similarities to HD. In order to determine
whether htt-HAP1 interactions could be important to the mo-
lecular basis of the phenotype observed in these mice, we have
cloned the mouse homologue of HAP1 (hap1). Expression
analysis revealed high levels of expression in both brain and
testis. The yeast two hybrid system was used to show that
hap1 does not interact with the N-terminal exon 1 transgene
protein.
2. Materials and methods
2.1. Cloning and analysis of mouse hap1 cDNA
A mouse whole brain (BALB/c P20) unidirectional cDNA library
(Stratagene, 937301) was screened with a mouse hap1 probe of 306 bp
(nt 889^1194 according to rat sequence [4], or nt 847^1152 according
to mouse sequence) obtained by RT-PCR of mouse brain RNA.
cDNAs were excised in vivo as pBluescript SK clones and sequenced
(Sequenase version 2.0, USB). Further 5P sequence (nt 310 to +6) was
determined by 5P RACE [9]. Sequence from the 3P UTR was obtained
using an ABI 377 sequencer with primers 40093 (TGGACGAGAC-
CACAAGGATG) and 40104 (GTCAGCCTCGGAAGTGCTGA).
Fragments of the hap1 cDNA were cloned into the bacterial expres-
sion vector pTrcHis B (Invitrogen) to ensure that recombinant pro-
teins of the predicted size were produced. Protein extracts, Western
blots and detection of recombinant protein with the anti-Xpress anti-
body were performed according to the manufacturer’s recommenda-
tions (Invitrogen).
2.2. Extraction and analysis of mouse RNA
RNA was isolated from a range of mouse tissues and Northern
blots were prepared as described [8]. Mouse RNA was reverse tran-
scribed in 75 mM KCl, 50 mM Tris-HCl pH 8.3, 3 mM MgCl2, 10
mM DTT, 0.5 mM dNTPs, 7 ng/Wl random hexamers with 0.8 U/Wl
RNasin (Promega), 13 U/Wl M-MLV RTase (BRL) for 10 min at
23‡C, 40 min at 37‡C and then for 10 min at 94‡C. The mhap1 probe
used to screen the mouse brain cDNA library was ampli¢ed using
primers designed from the rat sequence: 40085 (CATCTTCGAGAG-
GAGGCCTC) and 40088 (ATCCTGCATGTGGGAGCCAG). PCR
was performed in Promega bu¡er, 1.5 mM MgCl2, 0.2 mM dNTPs,
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4 ng/Wl primers with 0.02 U/Wl Taq DNA polymerase (Promega).
Cycling conditions were 90 s at 94‡C, 34U(30 s at 94‡C, 30 s at
55‡C, 90 s at 72‡C), 10 min at 72‡C.
2.3. Yeast two hybrid analysis
The 1.4 kbp BglII fragment from the mouse hap1 cDNA was li-
gated into the BamHI site of pGAD10 (Clontech). Insert orientation
was determined by restriction analysis and the reading frame veri¢ed
by sequencing. pBTM117C recombinant clones were generated to
produce the following fusion proteins: pBTMCAG51, htt aa 1^118
(51 glns); pBTMHD0.5, htt aa 1^171 (23 glns); pBTMHD1.7, htt aa
1^588 (23 glns); pBTMHD3.6, htt aa 1^1245 (23 glns). Yeast trans-
formations, selection systems and X-gal staining were as previously
described [6].
3. Results
3.1. Isolation of the mouse homologue of HAP1
A mouse total brain cDNA (BALB/c p20) library was
screened with a mouse RT-PCR product ampli¢ed with pri-
mers £anking the region of hap1 that binds to htt (aa 277^445
in rat). Of 11 unique cloned cDNAs hybridising to this probe,
two correspond to hap1-B (EMBL accession number
AJ000262). From the remaining nine clones it was possible
to deduce the mouse hap1-A sequence (accession numbers
AJ002271 and AJ002272); however, the majority of these
clones contained complex deletion events occurring between
the 3P hap1 coding region and the distal 3P UTR. These had
not arisen as a result of alternative splicing events when com-
pared to the genomic sequence (A. Sharp, C. Ross, unpub-
lished) and have most likely arisen as either cloning or reverse
transcription artefacts. 5P RACE was used to con¢rm that the
ATG initiation codon was at the equivalent location to that in
the rat hap1 cDNA and the 5P UTR sequence was determined
to nucleotide 310. From these clones, hap1-A and hap1-B
were found to be 3641 and 3130 nucleotides from the initia-
tion codon respectively. cDNA fragments were cloned into the
bacterial expression vector pTrcHis to con¢rm that hap1 fu-
sion proteins of the correct size were produced.
The predicted protein sequence for mouse hap1-A and
hap1-B (Fig. 1) shows a high degree of homology with the
rat sequence (92.5% identity for hap1-A and 92.7% identity
for hap1-B). In particular, the N-terminus (aa 276^363) and
C-terminus (396^450) of the region shown to bind to htt
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Fig. 1. Comparison of the amino acid sequence of the deduced
mouse hap1 and rat Hap1 proteins. The rat sequence is below the
mouse sequence and identical amino acids are indicated by a dash.
HAP1A and HAP1B di¡er at the C-terminus from residue 579 [4].
The region of rat HAP1 initially isolated by the yeast two hybrid
system [4] is indicated in bold.
Fig. 2. Northern blot analysis of hap1 mRNA. All lanes contained
20 Wg of total RNA. hap1 hybridisations were performed with a 2.0
kb 5P hap1-cDNA probe and mouse gapdh was used as a loading
control. A: Expression of hap1 in a range of adult mouse tissues:
the upper and lower panels show short and long exposures respec-
tively. B: Expression of hap1 in a range of adult mouse brain re-
gions. B = whole brain, L = liver, T = testis, K = kidney, H = heart,
M = muscle, U = lung, S = spleen, Y = thymus, st = striatum, cc = cere-
bral cortex, cb = cerebellum, ob = olfactory bulb, cl = colliculus.
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showed especially high homologies of 97.7% and 100% respec-
tively. In the coding sequence, the only alignment discrepancy
arose from the deletion of the rat codon 63 in the mouse
sequence. As expected, comparison of the 3P UTRs show a
higher degree of discrepancy including a deletion of the rat
sequence from nt 3576 to nt 3635.
3.2. Expression analysis of hap1
In order to analyse the expression of hap1 in mouse tissues,
we hybridised the entire coding region of hap1 to Northern
blots containing a panel of mouse tissue RNAs (Fig. 2). In
contrast to that observed in rat, the expression pattern of
mouse hap1 was not only restricted to brain but also showed
a high level of expression in testis, and a lower level in both
lung and spleen. In all cases the hybridisation signal appeared
as a doublet of 3.6 kb and 3.1 kb corresponding to the iso-
forms hap1-A and hap1-B respectively. Hap1-A appeared to
be the major hap1 isoform and the hap1-A/hap1-B expression
ratio did not di¡er between tissues. Comparison of mRNA
expression between di¡erent brain regions showed a much
higher level of expression in the olfactory bulb and colliculus
than in striatum, cerebral cortex or cerebellum. The expres-
sion of hap1 in mouse does not mirror the major sites of HD
neuropathology.
3.3. hap1 and htt protein interactions
As the htt-exon 1 protein has been shown to be su⁄cient to
induce in mice a neurological phenotype with similarities to
HD [8], we set out to determine whether mouse hap1 could
interact with this exon 1 protein (1^90 aa with 23 gln; 1^118
aa with 51 gln). The 1.4 kb BglII fragment coding for the ¢rst
473 amino acids of hap1 was cloned into the plasmid
pGAD10 to generate a GAL4 activator domain fusion protein
(pGAD-HAP1). This clone contained the entire hap1 frag-
ment found to bind to htt, initially allowing the cloning of
rat hap1 in the yeast two hybrid system [4]. pGAD-HAP1 was
transformed into yeast containing di¡erent N-terminal frag-
ments of htt fused to the binding domain of LEXA. Hap1 did
not interact with htt fragments containing the ¢rst 118 aa (51
gln repeat) and 171 aa (23 gln repeat) but did interact with htt
fragment 1^588 (Fig. 3). The interaction between HIP1 and
htt was used as a positive control and hap1 was found to
interact with these truncated htt fragments with a lower a⁄n-
ity than HIP1 (based on colony growth and X-gal staining).
The failure of hap1 to interact with the N-terminal 118 or 171
amino acids was not due to an absence of expression of htt in
these clones which have shown positive interactions when
tested with other proteins (Wanker, unpublished). The rat
hap1 clone was initially isolated with a 1^230 aa htt clone
and therefore, taken together, these results would indicate
that the amino acids at a position between 171^230 are essen-
tial for the interaction.
4. Discussion
The normal function of htt is thought to be involved in
vesicle tra⁄cking and cytoskeletal functions, as within neu-
rons htt is associated with vesicle membranes and microtu-
bules [10,11]. This role is supported by the isolation of the
htt interactors, HIP1 [5,6] and HAP1 [4]. HIP1 shows signi¢-
cant similarity to cytoskeleton proteins and is also enriched in
subcellular compartments containing vesicle-associated pro-
teins. HAP1 has recently been found to interact with cytoskel-
etal proteins, namely the p150Glued subunit of dynactin [12]
and the pericentriolar protein PCM-1 (Duo) [13]. Analysis
of axonal transport has shown that the rapid anterograde
accumulation of both htt and HAP1 is compatible with their
transport on vesicular membranes. Both proteins also show
retrograde movement, possibly necessary for their degradation
or for a function in retrograde membrane tra⁄cking [14].
Insights into the molecular pathology of HD have recently
been made from the analysis of the exon 1 HD transgenic
mice [15]. Immunocytochemistry with antibodies raised
against the N-terminus of htt (that detect the exon 1 protein)
and ubiquitin identi¢ed the presence of neuronal intranuclear
inclusions (NII) in symptomatic mice of all three lines prior to
the onset of the phenotype [15]. NII had previously been
described at the ultrastructural level in biopsy material from
HD caudate [16] and more recently have been detected by
immunocytochemistry with N-terminal antibodies in postmor-
tem HD brains [17,21]. Interestingly, the inclusions are not
detected with more C-terminal antibodies [17,21], and the
identi¢cation of an N-terminal 40 kDa fragment on Western
blots suggests that mutant htt is cleaved to release an N-ter-
minal fragment capable of aggregation [17].
This interpretation of the neuropathological ¢ndings is sup-
ported by the production of the exon 1 protein in vitro as a
glutathione S-transferase (GST) fusion protein, containing
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Fig. 3. Interaction of huntingtin and hap1 in the yeast two hybrid system. Activation of the HIS3 and lacZ reporter genes by the interaction
of hap1 or HIP1 with N-terminal fragments of htt as indicated. The Saccharomyces cerevisiae strain L40C harbouring pBTM117C,
pBTMCAG53, pBTMHD0.5, pBTMHD1.7 and pBTMHD3.6 was transformed with pGAD-HAP1 or pGAD-HIP1. Individual LeuTrp
transformants were selected on synthetic medium plates and replicated onto SD-Leu-Trp (L-W), SD-Leu-Trp-His (L-W-H) plates. The plates
were incubated at 30‡C for 3^5 days and replica ¢lters were made for the L-galactosidase assay (beta-gal).
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CAG repeats ranging from (CAG)20 to (CAG)122 [18]. On
removal of the GST tag, proteins containing pathogenic poly-
glutamine expansions form ¢brillar aggregates with an amy-
loid-like morphology which is consistent with polar zipper
interactions occurring between the polyglutamine repeats
[19]. It appears that the mutant htt protein is cleaved to gen-
erate an N-terminal fragment that moves to, or is taken to,
the nucleus, becomes ubiquitinated and forms insoluble amy-
loid-like aggregates. However, the order of these events and
the underlying molecular interactions are currently unknown.
It is becoming increasingly likely that the formation of ¢bril-
lar aggregates via polyglutamine interactions will be central to
the molecular pathology of all CAG repeat disorders sup-
ported by the recent report of NII in post-mortem MJD
[20], DRPLA [21,22] and SCA 1 brains [23].
We have shown that the htt amino acids 171^230, down-
stream of the polyglutamine stretch, are necessary for the
interaction between htt and hap1. Therefore, hap1 is excluded
from forming interactions with the exon 1 transgene protein
and from playing a role in the molecular pathology of the HD
transgenic mice. The demonstration that the exon 1 protein
can form amyloid-like aggregates in vitro may indicate that
further interactions are not necessary for the formation of
these aggregates, and as predicted from this ¢nding, neither
the NII in transgenic mice nor in postmortem HD brains are
immunoreactive for anti-HAP1 antibodies (S.W. Davies, per-
sonal communication; A. Sharp, unpublished). The selective
vulnerability of speci¢c neurons is likely to be due in part to
subtle di¡erences in expression levels [15]. However, hunting-
tin may be involved indirectly in cellular functions regulated
by ras-related signalling pathways (via HAP1^PCIP-10
(Duo)^Rac1) [13], which may be consistent with the altered
neuritic morphology seen in some surviving neurons [24].
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